# Haystack Oncology

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/haystack-oncology

- Industry: Biotechnology
- Headquarters: Baltimore, US
- Website: www.haystackoncology.com
- Total disclosed funding: $67M
- Latest round: Series A (Oct 17, 2022)
- Investors on record: 4

## About

Based in Maryland, US, and founded in 2021 by Bert Vogelstein, Kenneth Kinzler, and Nick Papadopoulos, Haystack Oncology is a biotechnology research firm that detects circulating tumor DNA in order to identify the lowest levels of ctDNA in blood to report residual, recurrent or resistant disease. In October 2022, Haystack Oncology raised USD 67 million in series A funding led by new investor Catalio Capital Management, with participation from other new investors Alexandria Venture Investments, Bruker Corporation, and Exact Ventures.

The company uses liquid biopsy technologies to detect the presence of traces of residual tumor DNA molecules left in the body after the initial treatment to help predict the recurrence of the disease. Haystack's testing is intended to inform clinical interventions by developing personalized diagnostic panels regardless of tumor origin.

The company intends to use the October 2022 funding for the continued development and planned 2023 commercialization of its personalized cancer diagnostic test that can detect as few as one mutant molecules in a million DNA molecules.

## Funding rounds

- Series A, Oct 17, 2022, $67M — Alexandria Venture Investments, Bruker Corporation, Catalio Capital Management, Exact Ventures

## Investors

- Alexandria Venture Investments (https://capitalatlas.ai/funds/alexandria-venture-investments) — Series A
- Bruker Corporation — Series A
- Catalio Capital Management (https://capitalatlas.ai/funds/catalio-capital-management) — Series A
- Exact Ventures — Series A